New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
04:55 EDTALKS, ALKS, RGDO, RGDO, LXRX, LXRX, ZIOP, ZIOP, RNA, RNA, AUXL, AUXL, XON, XON, SIGA, SIGA, GALE, GALE, MSTX, MSTXBiotech Industry Organization to hold a conference
16h Annual BIO CEO & Investor Conference is being held in New York on February 10-11.
News For ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX From The Last 14 Days
Check below for free stories on ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 16, 2014
16:48 EDTAUXLEndo delivers proposal to acquire Auxilium for $28.10 per share in cash, stock
Subscribe for More Information
16:48 EDTAUXLEndo delivers proposal to acquire Auxilium for $2.2B in cash, stock
Subscribe for More Information
09:25 EDTSIGAOn The Fly: Pre-market Movers
Subscribe for More Information
06:51 EDTSIGASIGA Technologies files petition for relief to supply Tecovirimat
Subscribe for More Information
September 15, 2014
07:55 EDTALKSAlkermes shares attractive ahead of Q1 catalysts, says Leerink
Leerink says its recent meeting with Alkermes management confirmed its conviction that the company is executing on its growth strategy. Leerink believes clinical trials for ALKS 8700 in multiple sclerosis, ALKS 7106 in abuse deterrent opiate analgesic and the Phase II trial for ALKS 3831 in schizophrenia are all billion dollar market opportunities that are not reflected in the current stock price. The firm finds the stock attractively valued ahead of clinical data readouts that start in early Q1 of 2015. It reiterates an Outperform rating on Alkermes with a $66 price target.
07:26 EDTMSTXPiper Jaffray to hold a conference
Subscribe for More Information
September 14, 2014
13:51 EDTAUXLAuxilium looks like 'overpriced tax shelter', Barron's says
Auxilium's (AUXL) acquisition of QLT (QLTI) for tax inversion purposes followed a collapse in Testim sales and the company "seems like an overpriced tax shelter," Barron's argues in a follow up article. Reference Link
September 12, 2014
13:30 EDTXONSynthetic Biologics confirms receipt of orphan drug designation for SYN-005
Subscribe for More Information
11:59 EDTAUXLAuxilium management to meet with Jefferies
Subscribe for More Information
09:14 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
September 11, 2014
18:35 EDTLXRXOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTLXRXLexicon publication of Phase 2b study shows LX4211 provides meaningful benefit
Subscribe for More Information
September 10, 2014
11:06 EDTLXRXLexicon management to meet with Jefferies
Subscribe for More Information
07:21 EDTAUXLAuxilium sees merger with QLT closing in Q4
Subscribe for More Information
September 9, 2014
17:03 EDTAUXLAuxilium announces corporate restructuring, will cut headcount approximately 30%
Subscribe for More Information
16:55 EDTAUXLAuxilium trading halted, pending news
Subscribe for More Information
07:13 EDTGALEGalena doses first patient in GALE-401 Phase 2 clinical trial
Subscribe for More Information
06:51 EDTALKSAlkermes management to meet with Leerink
Subscribe for More Information
September 8, 2014
08:12 EDTRNAProsensa reports positive results from DEMAND II study of drisapersen
Subscribe for More Information
08:01 EDTMSTXMast Therapeutics announces positive results from Phase 2 study of AIR001
Mast Therapeutics reported top-line results from a Phase 2 study of AIR001 inhalation solution for the treatment of pulmonary arterial hypertension. Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals earlier this year. In the primary efficacy analysis of the Phase 2 study, all doses showed improvement in median pulmonary vascular resistance. In the secondary efficacy analysis, all doses showed improvements in the median distances obtained in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Additionally, AIR001 was well-tolerated, with no treatment related serious adverse events. In particular, methemoglobin levels remained normal, which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use